Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): development of resistance in animals and possible impact on human and animal health - PubMed (original) (raw)

Review

. 2015 Sep;46(3):297-306.

doi: 10.1016/j.ijantimicag.2015.06.005. Epub 2015 Jun 29.

Marco Cavaleri 2, Keith Baptiste 3, Kari Grave 2, Kornelia Grein 2, Anja Holm 3, Helen Jukes 4, Ernesto Liebana 5, Antonio Lopez Navas 6, David Mackay 2, Anna-Pelagia Magiorakos 7, Miguel Angel Moreno Romo 8, Gérard Moulin 9, Cristina Muñoz Madero 6, Maria Constança Matias Ferreira Pomba 10, Mair Powell 11, Satu Pyörälä 12, Merja Rantala 12, Modestas Ružauskas 13, Pascal Sanders 9, Christopher Teale 14, Eric John Threlfall 15, Karolina Törneke 16, Engeline van Duijkeren 17, Jordi Torren Edo 18

Affiliations

Review

Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): development of resistance in animals and possible impact on human and animal health

Boudewijn Catry et al. Int J Antimicrob Agents. 2015 Sep.

Abstract

Since its introduction in the 1950s, colistin has been used mainly as a topical treatment in human medicine owing to its toxicity when given systemically. Sixty years later, colistin is being used as a last-resort drug to treat infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacteriaceae (e.g., Escherichia coli, Klebsiella pneumoniae), for which mortality can be high. In veterinary medicine, colistin has been used for decades for the treatment and prevention of infectious diseases. Colistin has been administered frequently as a group treatment for animal gastrointestinal infections caused by Gram-negative bacteria within intensive husbandry systems. Given the ever-growing need to retain the efficacy of antimicrobials used to treat MDR infections in humans, the use of colistin in veterinary medicine is being re-evaluated. Despite extensive use in veterinary medicine, there is limited evidence for the development of resistance to colistin and no evidence has been found for the transmission of resistance in bacteria that have been spread from animals to humans. Since surveillance for colistin resistance in animals is limited and the potential for such transmission exists, there is a clear need to reinforce systematic monitoring of bacteria from food-producing animals for resistance to colistin (polymyxins). Furthermore, colistin should only be used for treatment of clinically affected animals and no longer for prophylaxis of diseases, in line with current principles of responsible use of antibiotics.

Keywords: Colistin; Healthcare-associated infections; Livestock; Resistance.

Copyright © 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources